Incidence of Invasive Fungal Infections in Patients Initiating Ibrutinib and Other Small Molecule Kinase Inhibitors-United States, July 2016-June 2019

Clin Infect Dis. 2022 Aug 25;75(2):334-337. doi: 10.1093/cid/ciab1026.

Abstract

We analyzed administrative data to determine the 1-year incidence of invasive fungal infections (IFIs) in patients beginning small molecule kinase inhibitor (SMKI) therapy. The incidence of IFIs by small molecule kinase inhibitor ranged from 0.0% to 10.6%, with patients taking midostaurin having the highest incidence. An IFI developed in 38 of 1286 patients taking ibrutinib (3.0%).

Keywords: cancer; ibrutinib; invasive fungal infections; opportunistic infections; small molecule kinase inhibitors.

MeSH terms

  • Adenine* / adverse effects
  • Adenine* / analogs & derivatives
  • Humans
  • Incidence
  • Invasive Fungal Infections* / drug therapy
  • Invasive Fungal Infections* / epidemiology
  • Piperidines*
  • United States / epidemiology

Substances

  • Piperidines
  • ibrutinib
  • Adenine